The table below shows the adverse reactions of interest that happened during the study.

Adverse reactions of interest during this study:
- Dapagliflozin: 2.5% (54) participants experienced symptoms of low levels of liquids in the body, 1.6% (35) participants had kidney problems, 0.2% (4) participants had any bone fractures, 0.1% (3) participants had amputation, and 0.1% (2) participants had decreased blood sugar problems.
- Placebo: 1.4% (30) participants experienced symptoms of low levels of liquids in the body, 1.3% (27) participants had kidney problems, 0.1% (3) participants had any bone fractures, 0.1% (2) participants had amputation, and 0.3% (6) participants had decreased blood sugar problems. Additionally, 0.1% (1) participant had high levels of ketones in the blood caused by low levels of insulin.

How has this study helped patients and researchers?

This study helped researchers learn how dapagliflozin affects the kidneys in participants who have CKD.

Researchers look at the results of many studies to decide which treatments work best and are safest. This summary shows only the main results from this 1 study. Other studies may provide new information or different results.

Further clinical studies with dapagliflozin are planned.

11